Genmab A/S is set to acquire Merus NV for $8.0 billion in cash, with a premium of 41% per share over Merus’ closing stock price. The deal, funded through cash and debt financing, is expected to close in early 2026. The acquisition will not impact Genmab’s 2025 financial guidance and will add a potentially transformative therapy for head and neck cancer to its pipeline. Genmab projects annual sales of over $1 billion by 2029 for this therapy, with multi-billion-dollar revenue potential. The company will have four proprietary programs driving new drug launches by 2027 post-acquisition.

Read more at Nasdaq: Genmab To Acquire Merus In $8 Bln Cash Deal